Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.68 |
| ▸ | CSF1R | P07333 | 3/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.68 |
| ▸ | KIT | P10721 | 3/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.68 |
| ▸ | LCK | P06239 | 3/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | PLK4 | O00444 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 2/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.68 |
| ▸ | PAK4 | O96013 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | MET | P08581 | 2/20 | 0.68 |
| ▸ | FLT1 | P17948 | 2/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.68 |
| ▸ | TYK2 | P29597 | 2/20 | 0.68 |
| ▸ | AXL | P30530 | 2/20 | 0.68 |
| ▸ | FLT4 | P35916 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805651 | 1.00 | KDR (0.69) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4053991 | 1.00 | KDR (0.69) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4053989 | 1.00 | KDR (0.69) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4058055 | 0.99 | KDR (0.70) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4058051 | 0.99 | KDR (0.70) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL8086200 | 0.97 | KDR (0.71) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4897769 | 0.90 | KDR (0.71) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4064379 | 0.90 | KDR (0.71) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL4051141 | 0.89 | KDR (0.72) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL14067311 | 0.89 | KDR (0.76) | KDRFGFR1CSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009036066-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | KDR 2667/4885FGFR1 768/4885CSF1R 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.